TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39415796

Group type: EXPERIMENTAL
Intervention: Augmented reality (AR)-based telerehabilitation system
Number of subjects: 56

Group type: COMPARATOR
Intervention: Brochure-based rehabilitation program
Number of subjects: 56
Study: 39415799

Group type: EXPERIMENTAL
Intervention: Peer support intervention (Veteran peer Coaches Optimizing and Advancing Cardiac Health)
Number of subjects: 29
Study: 39415882

Group type: EXPERIMENTAL
Intervention: Extra soft cushioning material at the rear part of the shoe
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Cushioning under the forepart of the shoe
Number of subjects: 1000
Study: 39415900

Group type: EXPERIMENTAL
Intervention: MP0250 in combination with bortezomib and dexamethasone
Number of subjects: 33
Study: 39415923

Group type: EXPERIMENTAL
Intervention: Pirtobrutinib monotherapy
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy (AT-E)
Number of subjects: 773

Group type: COMPARATOR
Intervention: No antithrombotic therapy
Number of subjects: 773
Study: 39415930

Group type: EXPERIMENTAL
Intervention: Venetoclax (VEN) at doses of 400, 600, or 800 mg combined with liposomal vincristine (L-VCR) at 2.25 mg/m weekly
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of VEN and L-VCR
Number of subjects: 18
Study: 39416174

Group type: EXPERIMENTAL
Intervention: ADCT-701, a DLK1 targeting antibody-drug conjugate (ADC)
Number of subjects: 0
Study: 39416927

Group type: EXPERIMENTAL
Intervention: Juggling intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 20
Study: 39416950

Group type: EXPERIMENTAL
Intervention: Mini-dose dexmedetomidine (median 0.02 μg/kg/h)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 39416990

Group type: EXPERIMENTAL
Intervention: Quadrivalent Recombinant Influenza Vaccine (RIV)
Number of subjects: 3988

Group type: COMPARATOR
Intervention: Standard-Dose Inactivated Influenza Vaccine (SD IIV)
Number of subjects: 3988
Study: 39417106

Group type: EXPERIMENTAL
Intervention: DKN-01/nivolumab
Number of subjects: 0
Study: 39417128

Group type: EXPERIMENTAL
Intervention: Whole food, plant-based diet for 8 weeks
Number of subjects: 17
Study: 39417152

Group type: EXPERIMENTAL
Intervention: Daily 2 mg mometasone irrigations for 2 months in an optimized position as determined by a patient-specific 3D printed irrigation model (MG)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Daily 2 mg mometasone irrigations for 2 months with a head tilt of 90° to the side with fluid entering the lower nostril (BG)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Daily 2 mg mometasone irrigations for 2 months with standard head-forward and natural side-tilt position (CG)
Number of subjects: 62
Study: 39417218

Group type: EXPERIMENTAL
Intervention: PCV10 2+1 schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCV13 2+1 schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced 1+1 PCV dosing schedule
Number of subjects: 0
Study: 39417384

Group type: EXPERIMENTAL
Intervention: Music and Sleep Hygiene (MSH)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Sleep Hygiene alone (SH)
Number of subjects: 98
Study: 39418015

Group type: EXPERIMENTAL
Intervention: TPA
Number of subjects: 56

Group type: COMPARATOR
Intervention: C3F8
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Combined C3F8 and TPA
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 56
Study: 39418029

Group type: EXPERIMENTAL
Intervention: LEN-IE (lenvatinib 14 mg/m2 orally once daily + ifosfamide 3000 mg/m2 IV + etoposide 100 mg/m2 IV on days 1-3 of each cycle)
Number of subjects: 81

Group type: COMPARATOR
Intervention: IE (ifosfamide 3000 mg/m2 IV + etoposide 100 mg/m2 IV on days 1-3 of each cycle)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: LEN-IE
Number of subjects: 81

Group type: COMPARATOR
Intervention: IE
Number of subjects: 81
Study: 39418096

Group type: EXPERIMENTAL
Intervention: Remotely delivered exercise intervention group (12-week personalized avatar-guided home exercise program)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (electronic health diary)
Number of subjects: 40
Study: 39418210

Group type: EXPERIMENTAL
Intervention: MALS
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: immunoparalysis
Number of subjects: 210
Study: 39418242

Group type: EXPERIMENTAL
Intervention: In-phase bilateral upper limb exercises (30-60 minutes/session, 3 sessions/week for 12 weeks)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: In-phase bilateral upper limb exercises
Number of subjects: 5
Study: 39418289

Group type: EXPERIMENTAL
Intervention: Molecular markers correlated against standard of care MRI-targeted histology and oncological outcomes.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Molecular index derived from baseline (MolBL) and one year (MolFU) molecular profiles.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Radiological progression defined as a PRECISE score of 4 or 5.
Number of subjects: 60
Study: 39418340

Group type: EXPERIMENTAL
Intervention: Socazolimab (5 mg/kg) and nab-paclitaxel (260 mg/m2) Q3w
Number of subjects: 20
Study: 39418346

Group type: EXPERIMENTAL
Intervention: Palbociclib plus an aromatase inhibitor (AI)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Aromatase inhibitor (AI) alone
Number of subjects: 469
Study: 39418437

Group type: EXPERIMENTAL
Intervention: Parent proxy report
Number of subjects: 0

Group type: COMPARATOR
Intervention: Child self-report
Number of subjects: 0
Study: 39418443

Group type: EXPERIMENTAL
Intervention: Mindfulness strategy coping messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distraction strategy coping messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39418460

Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE) therapy
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE) therapy plus sertraline
Number of subjects: 130
Study: 39418626

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO)
Number of subjects: 131
Study: 39418644

Group type: EXPERIMENTAL
Intervention: CPX-351 plus venetoclax (CPX-351 30 units/m2: daunorubicin 13.2 mg/m2 and cytarabine 30 mg/m2; venetoclax 400 mg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CPX-351 plus venetoclax
Number of subjects: 35
Study: 39418669

Group type: EXPERIMENTAL
Intervention: Ketone monoester supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 39418824

Group type: EXPERIMENTAL
Intervention: Lavender oil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Peppermint oil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 39418854

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 108
Study: 39418883

Group type: EXPERIMENTAL
Intervention: Trastuzumab (T)
Number of subjects: 6281

Group type: EXPERIMENTAL
Intervention: Lapatinib + Trastuzumab (L + T)
Number of subjects: 6281

Group type: EXPERIMENTAL
Intervention: Trastuzumab followed by Lapatinib (T→L)
Number of subjects: 6281
Study: 39418916

Group type: COMPARATOR
Intervention: 25% isocaloric-restricted diets (Control diet)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: 25% isocaloric-restricted diets (Traditional Jiangnan diet)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: 25% isocaloric-restricted diets (Mediterranean diet)
Number of subjects: 253
Study: 39418986

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 633

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 633
Study: 39419035

Group type: EXPERIMENTAL
Intervention: rezvilutamide plus ADT
Number of subjects: 654
Study: 39419054

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with chemoradiotherapy
Number of subjects: 500

Group type: COMPARATOR
Intervention: Chemoradiotherapy alone
Number of subjects: 500
Study: 39419061

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with three cycles of intravenous paclitaxel (200 mg/m2) followed by adjuvant treatment.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with three cycles of intravenous paclitaxel (200 mg/m2).
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Adjuvant treatment following neoadjuvant treatment.
Number of subjects: 46
Study: 39419177

Group type: EXPERIMENTAL
Intervention: UM171-expanded single cord blood unit transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39419348

Group type: EXPERIMENTAL
Intervention: Sugammadex (2 mg/kg for TOF count ≥1 and 4 mg/kg for TOF count = 0)
Number of subjects: 51
Study: 39419367

Group type: EXPERIMENTAL
Intervention: Cluster analysis identifying five distinct phenotypes based on somatosensory and psychosocial characteristics pre- and post-surgery.
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Higher psychosocial distress and lower QoL correlated with elevated pain intensity one year post-surgery.
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale for pain intensity evaluation one year post-surgery.
Number of subjects: 184
Study: 39419473

Group type: EXPERIMENTAL
Intervention: Antenatal depressive symptoms
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Deficits in cold EF
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Hot EF
Number of subjects: 739
Study: 39419550

Group type: EXPERIMENTAL
Intervention: Pregnancy anxiety
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39419615

Group type: EXPERIMENTAL
Intervention: Internet-delivered guided self-help tinnitus treatment based on ACT combined with tailored sound therapy
Number of subjects: 164

Group type: COMPARATOR
Intervention: Tailored sound therapy alone
Number of subjects: 164
Study: 39419729

Group type: EXPERIMENTAL
Intervention: TGD-informed e-health intervention for 4 months
Number of subjects: 174

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: TGD-informed e-health intervention
Number of subjects: 174
Study: 39420060

Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET/CT
Number of subjects: 102

Group type: COMPARATOR
Intervention: 99mTc-MDP planar bone scan plus CT
Number of subjects: 102
Study: 39420169

Group type: EXPERIMENTAL
Intervention: TAK-003 (live-attenuated tetravalent dengue vaccine)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: TAK-003
Number of subjects: 200
Study: 39420312

Group type: EXPERIMENTAL
Intervention: Two-component educational hand hygiene intervention (training in hand-washing and supply of MONO-RUB)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Standard harm reduction services only (control group)
Number of subjects: 440
Study: 39420338

Group type: EXPERIMENTAL
Intervention: BDP/FF/G
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: BDP/FF
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 39420379

Group type: EXPERIMENTAL
Intervention: TARANG intervention (4 month duration, 4 sessions for husbands)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: TARANG intervention
Number of subjects: 41
Study: 39420468

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor-neprilysin inhibitor (ARNI)
Number of subjects: 26966

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor-neprilysin inhibitor (ARNI) with PDC ≥ 80%
Number of subjects: 26966

Group type: COMPARATOR
Intervention: Traditional RAS blockade
Number of subjects: 26966

Group type: COMPARATOR
Intervention: Traditional RAS blockade with PDC < 80%
Number of subjects: 26966
Study: 39420528

Group type: EXPERIMENTAL
Intervention: Low-calorie, high-protein diet from animal sources (HPA diet)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Low-calorie, high-protein diet from plant sources (HPP diet)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Both diets (HPA and HPP)
Number of subjects: 117
Study: 39420566

Group type: EXPERIMENTAL
Intervention: Culturally tailored financial well-being intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 39420668

Group type: EXPERIMENTAL
Intervention: Cervical cancer education
Number of subjects: 105
Study: 39420701

Group type: EXPERIMENTAL
Intervention: Robotic THA
Number of subjects: 138

Group type: COMPARATOR
Intervention: Conventional instruments (Control)
Number of subjects: 138
Study: 39420894

Group type: EXPERIMENTAL
Intervention: Gliclazide modified release
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 39421268

Group type: EXPERIMENTAL
Intervention: Animated overdose prevention and naloxone educational video (6-minute video)
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1004
Study: 39421431

Group type: EXPERIMENTAL
Intervention: difelikefalin
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 39421449

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39421567

Group type: EXPERIMENTAL
Intervention: MY-Skills intervention (yoga and self-management education), offered twice a week for eight weeks, each session lasting two hours.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 13
Study: 39421612

Group type: EXPERIMENTAL
Intervention: Cholesfytol NG (1,000 mg Amla fruit and 50 mg Olive fruit standardized extracts)
Number of subjects: 191
Study: 39421939

Group type: EXPERIMENTAL
Intervention: Highest tertile of plasma Gal-3
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Urine epidermal growth factor
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Gal-3
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Epidermal growth factor
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Urine biomarkers of kidney tubule injury
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: History of chronic kidney disease
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Primary composite outcome
Number of subjects: 175
Study: 39421941

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 527

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 527
Study: 39421943

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 703

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 703
Study: 39422068

Group type: EXPERIMENTAL
Intervention: Neutrophil-percentage-to-albumin ratio (NPAR)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Systemic immune-inflammation index (SII)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Systemic inflammatory response index (SIRI)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Machine-learning model (Random Forest algorithm)
Number of subjects: 240
Study: 39422200

Group type: EXPERIMENTAL
Intervention: Troponin ratio in TTS patients
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Troponin ratio
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Troponin ratio at a cut-off point of 0.12
Number of subjects: 108
Study: 39422261

Group type: EXPERIMENTAL
Intervention: CV0501 12 μg dose
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: CV0501 3 or 6 μg dose
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: CV0501
Number of subjects: 180
Study: 39422598

Group type: EXPERIMENTAL
Intervention: Fianlimab + cemiplimab (1 to 40 mg/kg of fianlimab plus 350 mg of cemiplimab every 3 weeks)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Fianlimab monotherapy (exact dosage not specified)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Transition from fianlimab monotherapy to combination therapy
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Fianlimab pharmacokinetics
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Fianlimab 1,600 mg Q3W (20 mg/kg in an 80-kg individual)
Number of subjects: 78
Study: 39422604

Group type: EXPERIMENTAL
Intervention: FAP-IL2v (10 mg, QW/Q2W) in combination with cetuximab (500 mg/m2, Q2W)
Number of subjects: 58
Study: 39422697

Group type: EXPERIMENTAL
Intervention: Co-targeting TGF-β and PDL1 pathways
Number of subjects: 48

Group type: COMPARATOR
Intervention: C1Q+ macrophage infiltrates
Number of subjects: 48
Study: 39422741

Group type: EXPERIMENTAL
Intervention: Eribulin 1.4 mg/m2 administered as a single dose after tumor removal.
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 7
Study: 39422764

Group type: EXPERIMENTAL
Intervention: Tislelizumab plus low-dose bevacizumab
Number of subjects: 32
Study: 39422837

Group type: EXPERIMENTAL
Intervention: 0.01% atropine for 2 years
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 0.1% loading dose for 6 months followed by 0.01% for 18 months
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 39422853

Group type: EXPERIMENTAL
Intervention: V0034CR (glycerol 15% and paraffin 10%)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: V0034CR
Number of subjects: 235
Study: 39422889

Group type: EXPERIMENTAL
Intervention: Educational video intervention (6-minute explainer video)
Number of subjects: 1971

Group type: COMPARATOR
Intervention: Control group (no educational video)
Number of subjects: 1971
Study: 39422911

Group type: EXPERIMENTAL
Intervention: 24-hour PAP
Number of subjects: 193

Group type: COMPARATOR
Intervention: Extended PAP
Number of subjects: 193
Study: 39422912

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily for 14 days
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 1250
Study: 39422935

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 39422941

Group type: EXPERIMENTAL
Intervention: Varoglutamstat
Number of subjects: 0
Study: 39422960

Group type: EXPERIMENTAL
Intervention: Gene delivery of brain derived neurotrophic factor (BDNF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nerve growth factor (NGF) gene therapy
Number of subjects: 0
Study: 39422992

Group type: EXPERIMENTAL
Intervention: Mission Reconnect (MR) intervention
Number of subjects: 364

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Qualitative outcomes from MR intervention
Number of subjects: 364
Study: 39423023

Group type: EXPERIMENTAL
Intervention: Albuminuria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapid Kidney Function Decline
Number of subjects: 0
Study: 39423043

Group type: EXPERIMENTAL
Intervention: Integrated Yoga and Psychological Intervention
Number of subjects: 0
Study: 39423145

Group type: EXPERIMENTAL
Intervention: Deucravacitinib 6 mg
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Deucravacitinib 12 mg
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 39423154

Group type: EXPERIMENTAL
Intervention: Altis single-incision sling
Number of subjects: 355

Group type: COMPARATOR
Intervention: Comparator group (full-length slings)
Number of subjects: 355
Study: 39423312

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 72
Study: 39423355

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1,200 mg) plus Bevacizumab (15 mg/kg)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Atezolizumab plus placebo
Number of subjects: 162
Study: 39423450

Group type: EXPERIMENTAL
Intervention: BCG-Japan (n=11)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Solvent (placebo) (n=13)
Number of subjects: 40
Study: 39423758

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: BCAA and glycine together
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Glycine alone
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: BCAA
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Glycine
Number of subjects: 167
Study: 39423759

Group type: EXPERIMENTAL
Intervention: Exercise-based rehabilitation
Number of subjects: 187

Group type: COMPARATOR
Intervention: Post-COVID-19 Syndrome patients
Number of subjects: 187
Study: 39423767

Group type: EXPERIMENTAL
Intervention: Quality Measures in Switzerland
Number of subjects: 1875

Group type: EXPERIMENTAL
Intervention: Quality Measures in Austria
Number of subjects: 1875

Group type: EXPERIMENTAL
Intervention: Reorganisational changes due to COVID-19
Number of subjects: 1875
Study: 39423874

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 1676

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1676
Study: 39423991

Group type: EXPERIMENTAL
Intervention: Alert during visits
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Message between visits
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180
Study: 39423993

Group type: EXPERIMENTAL
Intervention: Dronedarone in addition to usual care
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 3000
Study: 39424003

Group type: EXPERIMENTAL
Intervention: EUS-guided choledochoduodenostomy (EUS-CDS) with lumen-apposing metal stent (LAMS)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Placement of fully covered self-expandable metal stent (FCSEMS) through the LAMS
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: EUS-CDS with FCSEMS
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: EUS-CDS
Number of subjects: 27
Study: 39424007

Group type: EXPERIMENTAL
Intervention: Cold snare resection in clopidogrel users
Number of subjects: 263

Group type: COMPARATOR
Intervention: Cold snare resection in aspirin users
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Cold snare resection
Number of subjects: 263
Study: 39424070

Group type: EXPERIMENTAL
Intervention: Plant-protein blend
Number of subjects: 29

Group type: COMPARATOR
Intervention: Milk protein
Number of subjects: 29

Group type: COMPARATOR
Intervention: No added protein
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: All meal compositions
Number of subjects: 29